» Articles » PMID: 14583570

Risk Factors for Subclinical Atherosclerosis in a Prospective Cohort of Patients with Systemic Lupus Erythematosus

Overview
Journal Ann Rheum Dis
Specialty Rheumatology
Date 2003 Oct 30
PMID 14583570
Citations 103
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To evaluate traditional and non-traditional risk factors for subclinical atherosclerosis in systemic lupus erythematosus (SLE).

Methods: A prospective cohort of 78 patients with SLE without overt atherosclerotic disease was studied. SLE clinical and laboratory parameters, disease activity and damage, treatment and traditional risk factors for atherosclerosis were evaluated. At baseline (T1) and after five years' follow up (T2), the serum levels of anti-oxidised palmitoyl arachidonoyl phosphocholine (oxPAPC), anti-heat shock protein 65, and anti-beta(2)-glycoprotein I antibodies and C reactive protein were tested. At T2, intima-media thickness (IMT) was measured using duplex carotid sonography. Thickened intima, plaque, mean IMT (m-IMT), and maximum IMT (M-IMT) were assessed.

Results: A thickened intima was seen in 22/78 (28%) patients and plaque in 13/78 (17%). M-IMT and m-IMT were (mean (SD)) 0.77 (0.34) mm and 0.55 (0.15) mm, respectively. Patients with carotid abnormalities were significantly older, had higher blood pressure and total serum cholesterol levels, and had taken a higher prednisone cumulative dosage than those without any lesions. The carotid abnormalities were associated with renal disease and ECLAM >2 at T1, and with azathioprine treatment. In multivariate analysis, age and cumulative prednisone dose were associated with carotid abnormalities; age, hypertension, and anti-oxPAPC at T2 were correlated with higher M-IMT and m-IMT.

Conclusions: In patients with SLE some non-traditional risk factors for atherosclerosis were identified, the most important of which was the cumulative prednisone dose. The role of some traditional risk factors, such as age and hypertension, was also confirmed. The predictive value of the new immunological and inflammatory markers of atherosclerosis seems to be masked by some disease related features.

Citing Articles

Prevalence of cardiovascular events in a population-based registry of patients with systemic lupus erythematosus.

Joyce D, Berger J, Guttmann A, Hasan G, Buyon J, Belmont H Arthritis Res Ther. 2024; 26(1):160.

PMID: 39272198 PMC: 11401284. DOI: 10.1186/s13075-024-03395-6.


Deciphering Mechanisms, Prevention Strategies, Management Plans, Medications, and Research Techniques for Strokes in Systemic Lupus Erythematosus.

Al-Ewaidat O, Naffaa M Medicines (Basel). 2024; 11(7).

PMID: 39189161 PMC: 11348055. DOI: 10.3390/medicines11070015.


Three-dimensional speckle tracking echocardiography for evaluation of ventricular function in patients with systemic lupus erythematosus: relationship between duration of lupus erythematosus and left ventricular dysfunction by using global....

Akiash N, Abbaspour S, Mowla K, Moradi A, Madjidi S, Sharifi P Egypt Heart J. 2024; 76(1):79.

PMID: 38914877 PMC: 11196547. DOI: 10.1186/s43044-024-00511-4.


Cardiovascular risk factors and complications in patients with systemic lupus erythematosus with and without nephritis: a systematic review and meta-analysis.

Wong C, Ma B, Zhang D, Cheung W, Chan T, Yap D Lupus Sci Med. 2024; 11(1).

PMID: 38519060 PMC: 10961538. DOI: 10.1136/lupus-2024-001152.


Regulatory B Cells Evaluation in Systemic Lupus Erythematosus Patients with Subclinical Atherosclerosis and Secondary Antiphospholipid Syndrome.

Abdelaziz M, Fathi N, Hetta H, Abdel-Galeel A, Zidan M, Shawky E Mediterr J Rheumatol. 2024; 34(4):486-494.

PMID: 38282951 PMC: 10815535. DOI: 10.31138/mjr.03823.rbc.


References
1.
Howard G, Sharrett A, Heiss G, Evans G, Chambless L, RILEY W . Carotid artery intimal-medial thickness distribution in general populations as evaluated by B-mode ultrasound. ARIC Investigators. Stroke. 1993; 24(9):1297-304. DOI: 10.1161/01.str.24.9.1297. View

2.
Phadke K, Phillips R, Clarke D, Jones M, Naish P, Carson P . Anticardiolipin antibodies in ischaemic heart disease: marker or myth?. Br Heart J. 1993; 69(5):391-4. PMC: 1025099. DOI: 10.1136/hrt.69.5.391. View

3.
Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M . The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum. 1996; 39(3):363-9. DOI: 10.1002/art.1780390303. View

4.
Borhani N, Mercuri M, Borhani P, Buckalew V, CARR A, Kappagoda T . Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). A randomized controlled trial. JAMA. 1996; 276(10):785-91. View

5.
Hoppichler F, Lechleitner M, Traweger C, Schett G, Dzien A, Sturm W . Changes of serum antibodies to heat-shock protein 65 in coronary heart disease and acute myocardial infarction. Atherosclerosis. 1996; 126(2):333-8. DOI: 10.1016/0021-9150(96)05931-x. View